Story thread · 2 reports / 2 sources
Novo Still Has Work to Do to Build Investor Confidence, CEO Says
bloomberg.com · 3h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopoly on all the good ideas," Doustdar tells Bloomberg Television. "When there is a gap, strategically or scientifically, we're looking outside to see how we can fill the gaps." (Source: Bloomberg)
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.